Related Experiment Video

Updated: Dec 23, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.9K

Heart transplantation after SynCardia® total artificial heart implantation

Michiel Morshuis1, Sebastian V Rojas1, Kavous Hakim-Meibodi1

  • 1Clinic for Thoracic- and Cardiovascular Surgery, Heart and Diabetes Centre North Rhine Westphalia, Bad Oeynhausen, Germany.

Annals of Cardiothoracic Surgery
|April 21, 2020
PubMed

Insights

Outcomes after heart transplantation are poorer for patients receiving the SynCardia total artificial heart (TAH) compared to other mechanical circulatory support (MCS) devices. Improved risk stratification is needed for these TAH recipients.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Transplantation Medicine

Background:

  • The SynCardia total artificial heart (TAH) is the sole approved TAH device.
  • This study reviews single-center outcomes of SynCardia TAH recipients, focusing on subsequent heart transplantation.
  • Experience with the SynCardia TAH device is evaluated in the context of heart transplantation.

Purpose of the Study:

  • To assess the outcomes of heart transplantation in patients previously supported by the SynCardia total artificial heart (TAH).
  • To compare the survival rates of transplanted TAH patients with those who received left ventricular assist devices (LVADs), biventricular assist devices (BVADs), or no mechanical circulatory support (non-MCS).

Main Methods:

  • Retrospective analysis of transplanted SynCardia TAH patients (2001-2019).
  • Comparison group included transplanted LVAD, BVAD, and non-MCS patients.
  • Outcomes were analyzed to identify differences in survival post-transplantation.

Main Results:

  • Only 37.3% (n=69) of 193 SynCardia TAH patients underwent transplantation.
  • The majority of transplanted TAH patients (81.2%) were in high-urgency status.
  • Survival was significantly poorer in transplanted SynCardia TAH patients versus LVAD, BVAD, and non-MCS groups (P=0.008).

Conclusions:

  • Heart transplantation outcomes in SynCardia TAH patients are notably worse than in other groups.
  • Distinct risk stratification is essential for improving outcomes in heart transplantation following TAH support.
  • Further research is needed to refine patient selection and management for TAH recipients undergoing transplantation.
Abstract

Keywords:
Mechanical circulatory support (MCS)cardiac transplantationtotal artificial heart (TAH)

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
228
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
184
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
339